Health
Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial
LAKE FOREST, Ill., January 09, 2026--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist.
About this update from Assertio Holdings, Inc.
[{"type":"text","content":"Peer-reviewed publication in "The Oncologist" is now available online","length":79,"tagName":"p","attribs":{}},{"type":"text","content":"Investigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day dosing","length":129,"tagName":"p","attribs":{}},{"type":"text","content":"LAKE FOREST, Ill., January 09, 2026--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist.","length":330,"tagName":"p"},{"type":"text","content":"In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an effective neutrophil recovery and an adverse event profile similar to that seen with next-day dosing.","length":306,"tagName":"p"},{"type":"text","content":"Howard Franklin, M.D., Senior Vice President of Medical with Assertio: "We were encouraged to see that same-day dosing of Rolvedon demonstrated efficacy and safety similar to dosing one day after chemotherapy. Assertio is proud to lead this study that provides data that supports a more convenient administration schedule for Rolvedon. Thank you to the investigators and patients who participated in this study."","length":422,"tagName":"p"},{"type":"text","content":"Lee Schwartzberg, M.D., Professor of Clinical Medicine with Renown Health-Pennington Cancer Institute, Reno, Nevada, and a study author: "Febrile neutropenia (FN) is a significant risk factor among patients with early-stage breast cancer who are undergoing chemotherapy. This important study provides the oncology community with much-needed insight into the potential utility of same-day dosing of GCSF therapy with Rolvedon in these patients."","length":454,"tagName":"p"},{"type":"text","content":"The Oncologist is the official peer-reviewed medical journal for the Society for Translational Oncology. Results of this study were first presented in December 2024 as part of the San Antonio Breast Cancer Symposium.","length":216,"tagName":"p"},{"type":"text","content":"Study Summary","l...